Blood Stream Infections by Candida glabrata and Candida krusei: A Single-Center Experience
Open Access
- 1 January 2009
- journal article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 24 (3), 263-9
- https://doi.org/10.3904/kjim.2009.24.3.263
Abstract
The increasing incidence of Candida glabrata and Candida krusei infections is a significant problem because they are generally more resistant to fluconazole. We compared the risk factors associated with C. glabrata and C. krusei fungemia with Candida albicans fungemia and examined the clinical manifestations and prognostic factors associated with candidemia. We retrospectively reviewed demographic data, risk factors, clinical manifestations, and outcomes associated with C. glabrata and C. krusei fungemia at a tertiary-care teaching hospital during a 10-years period from 1997 to 2006. During the study period, there were 497 fungemia episodes. C. glabrata fungemia accounted for 23 episodes and C. krusei fungemia accounted for 8. Complete medical records were available for 27 of these episodes and form the basis of this study. Compared to 54 episodes of C. albicans fungemia, renal insufficiency and prior fluconazole prophylaxis were associated with development of C. glabrata or C. krusei fungemia. The overall mortality was 67%. The fungemia-related mortality of C. glabrata and C. krusei was higher than that of C. albicans (52 vs. 26%, p=0.021). Empirical antifungal therapy did not decrease the crude mortality. Multiple logistic regression analysis showed that high APACHE II scores, catheter maintenance, and shock were independently associated with an increased risk of death. Renal insufficiency and prior fluconazole prophylaxis were associated with the development of C. glabrata or C. krusei fungemia. Fungemia-related mortality of C. glabrata or C. krusei was higher than that of C. albicans. Outcomes appeared to be related to catheter removal, APACHE II scores, and shock.Keywords
This publication has 28 references indexed in Scilit:
- Active Surveillance of Candidemia, AustraliaEmerging Infectious Diseases, 2006
- Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional StudyClinical Infectious Diseases, 2006
- A Prospective Observational Study of Candidemia: Epidemiology, Therapy, and Influences on Mortality in Hospitalized Adult and Pediatric PatientsClinical Infectious Diseases, 2003
- Candidemia at a Tertiary-Care Hospital: Epidemiology, Treatment, Clinical Outcome and Risk Factors for DeathEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms StudyJournal of Clinical Microbiology, 2002
- Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcomeBone Marrow Transplantation, 2001
- Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrataJournal of Hospital Infection, 2001
- Candidemia in Allogeneic Blood and Marrow Transplant Recipients: Evolution of Risk Factors after the Adoption of Prophylactic FluconazoleThe Journal of Infectious Diseases, 2000
- Editorial Response: The Contribution of Fluconazole to the Changing Epidemiology of Invasive Candidal InfectionsClinical Infectious Diseases, 1997
- Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitalsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1996